Iovance Biotherapeutics Inc. Common Stock vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.69 (market cap $6.04B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.74 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 27.9× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Emerging Markets Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| IOVA | VWO | |
|---|---|---|
Market Cap | $6.04B | $168.50B |
Volume | 14,805,993 | 9,650,999 |
Sector | Health | — |
52-Week High | $14.82 | $61.44 |
52-Week Low | $1.81 | $52.42 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $5.97B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VWO trades at $59.67, down 0.3% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic slowdown weighs on performance. Recent news highlights institutional accumulation with Allianz and Alamar Capital increasing positions, though comparisons show developed market ETFs like VEA offer lower expense ratios and higher yields.
Outlook remains cautious with technical resistance at $60 and support at $59. Emerging markets face headwinds from China's weak retail and property sectors, though AI infrastructure spending offers partial offset. Investors should monitor dollar weakness as a potential catalyst for EM equities while weighing concentration risks in single-country exposures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →